Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumasiran in Primary Hyperoxaluria Type 1
NCT03681184Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Primary Hyperoxaluria Type 1 (PH1) comparing Lumasiran/Lumasiran with Placebo/Lumasiran (2 arms). Primary endpoint: Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6. Started Nov 2018; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT03681184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681184.